MediPharm Labs Enters Denmark Healthcare Cannabis Industry, Secures New White-Label Provide Shoppers

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a worldwide leader in specialized, study-driven pharmaceutical-excellent cannabis extraction, distillation and derivative merchandise, these days announced it will provide cannabis concentrate merchandise in Denmark to two new health-related cannabis buyers below two separate white-label agreements. These buyers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initial provide agreements for the export of completed merchandise to Denmark.

Denmark granted sufferers legal access to cannabis-primarily based medicinal merchandise two years ago as portion of a 4-year pilot system. The system delivers sufferers with secure solution access and national well being authorities with patient information that they can use to comprehend usage and efficacy. According to info complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred sufferers (mainly ladies amongst the ages of 42-64) received cannabis-primarily based medicinal merchandise from 429 prescribing medical doctors below this system in 2019.

“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis market place for medicinal, wellness and adult use applications and these agreements represent a further step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related market place with new and revolutionary health-related cannabis focused merchandise positions us for added development in Europe and adds to MediPharm Labs all-crucial physique of understanding that we are leveraging to improve the design and style of our formulations for sufferers and shoppers everywhere.”

Below the agreements, 1 which has an initial two-year term and the second a 1-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil merchandise that will be white-labeled for distribution.

MediPharm Labs anticipates delivery to its buyers to start in October 2020, pending regulatory approval by applicable well being authorities.

GMP Certification Ignites Development for MediPharm Labs Australia

“Since the starting of 2020, MediPharm Labs Australia has secured various extremely desirable domestic and international provide agreements with higher excellent partners, now which includes new buyers in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new small business wins are a clear and crucial validation of our choice to make a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs developing profile and reputation. We appear forward to ramping up production below all of these agreements.”

MediPharm Labs Australia received its Great Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May possibly 2020, which enables it to sell cannabis APIs and completed merchandise to nations across the EU, which includes Denmark. The Business entered into its initial European white-label cannabis provide agreement that similar month with Therismos Restricted.

About Denmark’s Healthcare Cannabis Industry

Denmark launched its 4-year health-related cannabis pilot system on January 1st, 20181. Post-harvest Great Manufacturing Processes (GMP) is essential for distribution of health-related cannabis merchandise in Denmarktwo.

By way of the system, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 locations: discomfort triggered by various sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The suggestions published by the Danish Medicines Agency are primarily based on an comprehensive assessment of literature as effectively as assessments of: cannabis schemes in the Netherlands, Canada and Israel preceding cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical excellent cannabis oil and concentrates and sophisticated derivative merchandise using a Great Manufacturing Practices certified facility with ISO normal constructed clean rooms. MediPharm Labs has invested in an specialist, study-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 main extraction lines for delivery of pure, trusted and precision -dosed cannabis merchandise for its buyers. By way of its wholesale and white label platforms, they formulate, customer-test, method, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based merchandise to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For additional info, please make contact with:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E-mail: [email protected]
Web-site: www.medipharmlabs.com

______________________________
1 Medicinal Cannabis Pilot Plan. Retrieved: https://laegemiddelstyrelsen.dk/en/particular/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Healthcare Cannabis Industry in Denmark &amp Europe. Retrieved: https://www.openaccessgovernment.org/the-health-related-cannabis-market place-in-denmark-europe/80721/
three The Danish Healthcare Cannabis Pilot Programme: Placing the Patient Initially. Retrieved: https://www.healtheuropa.eu/the-danish-health-related-cannabis-pilot-programme-placing-the-patient-initial/92991/

CAUTIONARY NOTE Relating to FORWARD-Searching Details:

This news release consists of “forward-seeking information” and “forward-seeking statements” (collectively, “forward-seeking statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical truth, are forward-seeking statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that includes discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or efficiency (generally but not constantly employing phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or final results “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical truth and may possibly be forward-seeking statements. In this news release, forward-seeking statements relate to, amongst other issues, the profitable efficiency of the agreements and shipping of merchandise thereunder as planned added development in Europe and enhancing the design and style of formulations. Forward-seeking statements are necessarily primarily based upon a quantity of estimates and assumptions that, though thought of affordable, are topic to recognized and unknown dangers, uncertainties, and other elements which may possibly lead to the actual final results and future events to differ materially from these expressed or implied by such forward-seeking statements. Such elements involve, but are not restricted to: basic small business, financial, competitive, political and social uncertainties the inability of MediPharm Labs to receive sufficient financing the delay or failure to acquire regulatory approvals and other elements discussed in MediPharm Labs’ filings, out there on the SEDAR internet site at www.sedar.com. There can be no assurance that such statements will prove to be correct, as actual final results and future events could differ materially from these anticipated in such statements. Accordingly, readers should really not spot undue reliance on the forward-seeking statements and info contained in this news release. Except as essential by law, MediPharm Labs assumes no obligation to update the forward-seeking statements of beliefs, opinions, projections, or other elements, should really they modify.

Latest posts